tetano
Editor, Senior Moderator
Sci Adv
. 2021 Aug 11;7(33):eabg5995.
doi: 10.1126/sciadv.abg5995. Print 2021 Aug.
Cell therapy strategies for COVID-19: Current approaches and potential applications
Mark M Zaki[SUP] 1 2 [/SUP], Emal Lesha[SUP] 1 3 [/SUP], Khaled Said[SUP] 4 [/SUP], Kiavash Kiaee[SUP] 4 [/SUP], Lindsey Robinson-McCarthy[SUP] 4 [/SUP], Haydy George[SUP] 1 [/SUP], Angy Hanna[SUP] 5 [/SUP], Evan Appleton[SUP] 4 6 [/SUP], Songlei Liu[SUP] 4 6 [/SUP], Alex H M Ng[SUP] 7 4 6 [/SUP], Parastoo Khoshakhlagh[SUP] 7 4 6 [/SUP], George M Church[SUP] 7 4 6 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) continues to burden society worldwide. Despite most patients having a mild course, severe presentations have limited treatment options. COVID-19 manifestations extend beyond the lungs and may affect the cardiovascular, nervous, and other organ systems. Current treatments are nonspecific and do not address potential long-term consequences such as pulmonary fibrosis, demyelination, and ischemic organ damage. Cell therapies offer great potential in treating severe COVID-19 presentations due to their customizability and regenerative function. This review summarizes COVID-19 pathogenesis, respective areas where cell therapies have potential, and the ongoing 89 cell therapy trials in COVID-19 as of 1 January 2021.
. 2021 Aug 11;7(33):eabg5995.
doi: 10.1126/sciadv.abg5995. Print 2021 Aug.
Cell therapy strategies for COVID-19: Current approaches and potential applications
Mark M Zaki[SUP] 1 2 [/SUP], Emal Lesha[SUP] 1 3 [/SUP], Khaled Said[SUP] 4 [/SUP], Kiavash Kiaee[SUP] 4 [/SUP], Lindsey Robinson-McCarthy[SUP] 4 [/SUP], Haydy George[SUP] 1 [/SUP], Angy Hanna[SUP] 5 [/SUP], Evan Appleton[SUP] 4 6 [/SUP], Songlei Liu[SUP] 4 6 [/SUP], Alex H M Ng[SUP] 7 4 6 [/SUP], Parastoo Khoshakhlagh[SUP] 7 4 6 [/SUP], George M Church[SUP] 7 4 6 [/SUP]
Affiliations
- PMID: 34380619
- DOI: 10.1126/sciadv.abg5995
Abstract
Coronavirus disease 2019 (COVID-19) continues to burden society worldwide. Despite most patients having a mild course, severe presentations have limited treatment options. COVID-19 manifestations extend beyond the lungs and may affect the cardiovascular, nervous, and other organ systems. Current treatments are nonspecific and do not address potential long-term consequences such as pulmonary fibrosis, demyelination, and ischemic organ damage. Cell therapies offer great potential in treating severe COVID-19 presentations due to their customizability and regenerative function. This review summarizes COVID-19 pathogenesis, respective areas where cell therapies have potential, and the ongoing 89 cell therapy trials in COVID-19 as of 1 January 2021.